Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 10/20 | 0.71 |
| ▸ | PLA2G2A | P14555 | 5/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12820064 | 0.89 | PLA2G2C (0.56) | PLA2G2CPLA2G2AACACBTAS1R3TAS1R1 | |
| SCHEMBL6547737 | 0.84 | PLA2G2C (0.62) | PLA2G2CPLA2G2ACA1CA2 | |
| SCHEMBL22083015 | 0.82 | PLA2G2C (0.46) | PLA2G2CPLA2G2ACA1CA2ACACB | |
| SCHEMBL11506429 | 0.80 | PLA2G2C (0.59) | PLA2G2CPLA2G2ACA1CA2TAS1R3 | |
| SCHEMBL17506705 | 0.80 | TAS1R3 (0.47) | PLA2G2CPLA2G2ACA1CA2ACACB | |
| SCHEMBL13715798 | 0.80 | PLA2G2C (0.59) | PLA2G2CPLA2G2ACA1CA2 | |
| SCHEMBL13888611 | 0.80 | TAS1R3 (0.47) | PLA2G2CPLA2G2ACA1CA2ACACB | |
| SCHEMBL20925463 | 0.79 | PLA2G2C (0.62) | PLA2G2CPLA2G2ACA1CA2TAS1R3 | |
| SCHEMBL13587912 | 0.79 | PLA2G2C (0.57) | PLA2G2CPLA2G2ACA1CA2 | |
| SCHEMBL2666554 | 0.79 | PLA2G2C (0.67) | PLA2G2CPLA2G2ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021257568-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |